West Pharmaceutical Services : J.P. Morgan Healthcare Conference Presentation
January 18, 2021 at 08:42 pm
Share
West Pharmaceutical Services, Inc.
Eric M. Green
President & CEO
JP Morgan Conference | January 13, 2021
Safe Harbor Statement
Cautionary Statement Under the Private Securities Litigation Reform Act of 1995
This presentation and any accompanying management commentary contain "forward- looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product development and operational performance. Each of these statements is based on preliminary information, and actual results could differ from any preliminary estimates.
We caution investors that the risk factors listed under "Cautionary Statement" in our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially from those estimated or predicted in the forward-looking statements. You should evaluate any statement in light of these important factors. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Non-U.S. GAAP Financial Measures
Certain financial measures included in these presentation materials, or which may be referred to in management's discussion of the Company's results and outlook, have not been calculated in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"), and therefore are referred to as non-U.S. GAAP financial measures. Non-U.S. GAAP financial measures should not be considered in isolation or as an alternative to such measures determined in accordance with U.S. GAAP. Please refer to "Reconciliation of Non-U.S. GAAP Financial Measures" at the end of these materials for more information.
Trademarks
Registered trademarks used in this report are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless noted otherwise. Daikyo Crystal Zenith® and Daikyo® are registered trademarks of Daikyo Seiko, Ltd.
2
West Is a Global Leader in Containment and Delivery of Injectable Medicines.
MISSION
We contain and deliver injectable therapies that improve patients' lives
VISION
To be the world leader in the integrated containment and delivery of injectable medicines
VALUES
Passion for Customers Leadership in Quality One West Team
3
A Growing Business Well-Positioned for Success.
Net Sales* by
Net Sales* by
GEOGRAPHY
PRODUCT CATEGORY
8%
24%
45%
43%
49%
5%
26%
Americas
PROPRIETARY PRODUCTS
High-Value Components
Europe, Middle East, Africa
Standard Packaging
Asia Pacific
Delivery Devices
Contract-Manufactured
Products
* September 2020 YTD
Net Sales* by
MARKET GROUP
24%29%
28%19%
PROPRIETARY PRODUCTS
Biologics
Generics
Pharma
Contract-Manufactured Products
Team Members
10,000+
Globally
Locations
50
25 Manufacturing Sites
Customers
>2,000
Across Healthcare Industry
Products
>100M
Components Daily
Patents
313
2019-2020
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
West Pharmaceutical Services Inc. published this content on 13 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 January 2021 20:41:02 UTC
West Pharmaceutical Services, Inc. specializes in the design, manufacture and marketing of components and systems for the containment and delivery of injectable drugs. The group offers packaging, components for syringes, cartridge systems, auto-injection devices, accessories for vials, specialty components, etc. Net sales break down by family of products as follows:
- own manufactured products (81.8%);
- products manufactured under contract (18.2%).
Net sales are distributed geographically as follows: the United States (42.3%), Germany (16.8%), Ireland (8.7%), France (7.5%), Europe (12.1%) and other (12.6%).
WEST PHARMACEUTICAL SERVICES, INC. 
